A Study of MK-2060 in Healthy Participants (MK-2060-016)
A Single Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous Infusion and Intravenous Bolus Administration of MK-2060 in Healthy Participants
Sponsor: Merck Sharp & Dohme LLC
Listed as NCT06582602, this PHASE1 trial focuses on Venous Thrombosis and remains completed. Sponsored by Merck Sharp & Dohme LLC, it has been updated 5 times since 2024, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
5 versions recorded-
Jun 2025 — Present [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Feb 2025 — Jun 2025 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jan 2025 — Feb 2025 [monthly]
Recruiting PHASE1
-
Nov 2024 — Jan 2025 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Oct 2024 — Nov 2024 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Merck Sharp & Dohme LLC
For direct contact, visit the study record on ClinicalTrials.gov .